Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery
Neoadjuvant pembrolizumab does not significantly increase postoperative complications. Surgical timing appears to be a modifiable factor influencing outcomes.
Authors
- Fabien Reyal (ORCID: https://orcid.org/0000-0002-2318-3589)
- Virginie Fourchotte
- Enora Laas (ORCID: https://orcid.org/0000-0003-3875-4011)
- Thomas Gaillard (ORCID: https://orcid.org/0000-0002-7062-9379)
- Luc Cabel (ORCID: https://orcid.org/0000-0001-5515-9180)
- David Sammon (ORCID: https://orcid.org/0000-0001-6138-0105)
- Benoît Couturaud (ORCID: https://orcid.org/0000-0002-1192-5354)
- Lauren Darrigues (ORCID: https://orcid.org/0000-0002-2104-6046)
- Kim Cao (ORCID: https://orcid.org/0000-0003-2475-1821)
- C. Bonneau
- Jean-Guillaume Féron
- Delphine Loirat
- Capucine Barjot
Institutions
- Institut Curie (FR)
Publication Details
- Journal
- European Journal of Surgical Oncology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1016/j.ejso.2025.110511
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.01